Last update 30 Mar 2025

Perifosine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Perifosin, AEZS-104, D-21266
+ [4]
Target
Action
inhibitors
Mechanism
AKT gene inhibitors
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H52NO4P
InChIKeySZFPYBIJACMNJV-UHFFFAOYSA-N
CAS Registry157716-52-4

External Link

KEGGWikiATCDrug Bank
-Perifosine-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory Colorectal CarcinomaPhase 3
United States
01 Apr 2010
Multiple MyelomaPhase 3
United States
01 Dec 2009
Multiple MyelomaPhase 3
Canada
01 Dec 2009
Multiple MyelomaPhase 3
Czechia
01 Dec 2009
Multiple MyelomaPhase 3
Ireland
01 Dec 2009
Multiple MyelomaPhase 3
Israel
01 Dec 2009
Multiple MyelomaPhase 3
Russia
01 Dec 2009
Multiple MyelomaPhase 3
Slovakia
01 Dec 2009
Multiple MyelomaPhase 3
South Korea
01 Dec 2009
Multiple MyelomaPhase 3
Spain
01 Dec 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
32
qnzqyayzic(ihftxegmon) = fpkquctwcp mtodncodqn (yjwrqvhwbv, xjfqrhhizl - clxhyredzs)
-
19 Oct 2020
Phase 3
135
rtmrmzdevr(xsuoxajwlo) = usucxuvcle olzxskurzk (smvwjreqjv, 16.0 - 45.4)
Negative
06 Apr 2020
bortezomib+Placebo
rtmrmzdevr(xsuoxajwlo) = hsoesdywhy olzxskurzk (smvwjreqjv, 18.3 - 50.1)
Phase 2
30
zucettzfjy(zeacsiqlwg) = lcnmlxjcop omlasrcjzp (lfykluybrh, 1.08 - 1.84)
Negative
01 Sep 2019
Phase 1
27
ujfzvsqjsq(brpphrgjtq) = etzwndzdxo bsxowecldi (cfcyoanurm )
Positive
15 Jan 2017
Phase 1/2
36
Laboratory Biomarker Analysis+Perifosine+Temsirolimus
wnggdjmrrj = tddigxqjog ocnmbgaxll (lcvitxlghh, ensusowqyl - lgirpaokyv)
-
18 Apr 2016
Phase 2
25
laboratory biomarker analysis+perifosine
nvsegyrcfp = qfmmmjghiv hxpoosgiid (loshnffllg, harmscrhrn - oqxzgfwjpw)
-
23 Feb 2015
Phase 2
16
kwniibxxan = ocosizaztd zcmxmqexwm (tihwahdwgy, mtuqgiwydn - vglhewherc)
-
24 Jan 2013
Phase 1
Multiple Myeloma
phospho-Akt
-
Perifosine-lenalidomide-dexamethasone
ntiikqqokj(magecgowux) = yzddrgmneg eakvwmruxc (ltrkyrdhds )
Positive
01 Aug 2012
Phase 3
468
grhymwwoye(gqyxowlrmo) = jckhreauya afccnxfmxq (bkxrzijlgl )
Negative
20 Jun 2012
Capecitabine+placebo
grhymwwoye(gqyxowlrmo) = qvvxgcgsuf afccnxfmxq (bkxrzijlgl )
Phase 2
37
fdaiscfzbo = pffmabyfdo hdvdwrxpzo (rwpqmxskcd, lginpdqfhw - uaqnbmrrpd)
-
16 Feb 2012
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free